The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

INTRODUCTION: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes (CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available on the optimal schedule of administration of this drug. The aim of the pr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Caorsi, Roberta, Lepore, Loredana, Zulian, Francesco, Alessio, Maria, Stabile, Achille, Insalaco, Antonella, Finetti, Martina, Battagliese, Antonella, Martini, Giorgia, Bibalo, Chiara, Martini, Alberto, Gattorno, Marco
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2013
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672768/
https://ncbi.nlm.nih.gov/pubmed/23442610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4184
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg